DMDavid McDonnell

David McDonnell

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


David McDonnell has a total of 173 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Aripiprazole Lauroxil: Development and Evidence-Based Review of a Long-Acting Injectable Atypical Antipsychotic for the Treatment of Schizophrenia

    by Leslie Citrome, Christoph U Correll, Andrew J Cutler, Martin Dunbar, Amber R Hoberg, Craig Hopkinson, Gregory W Mattingly, James McGrory, Bhaskar Rege, Peter J Weiden, et al.

    This review article describes why and how aripiprazole was formulated as aripiprazole lauroxil (AL), an extended-release antipsychotic agent that is delivered via a long-acting injectable formulation, and the clinical trials investigating its use. AL was formulated as an inactive prodrug of aripiprazole using LinkeRx® technology to provide a prolonged-release antipsychotic with predictable dissolution over time. The resulting AL pharmacokinetic profile is characterized by a long half-life and little peak-to-trough aripiprazole concentration variability across dosing intervals of every 1 month, every 6 weeks, and every 2 months. The prodrug technology was further refined to develop an AL initiation formulation with a somewhat faster release of aripiprazole, eliminating the need for a 21-day oral aripiprazole supplementation period. With this initiation formulation, AL treatment can be started in 1 day. Key AL characteristics, including pharmacokinetic profile and efficacy, safety, and tolerability data, are presented. In addition to the efficacy and safety established in clinical trials of oral aripiprazole, a placebo-controlled 12-week pivotal study investigated AL 441 mg and 882 mg monthly regimens in patients with acutely exacerbated schizophrenia and provided efficacy and safety information that led to US Food and Drug Administration approval in 2015. Thereafter, studies established the long-term safety profile and durability of the AL treatment effect. The 25-week, active-controlled ALPINE study evaluated the feasibility and effectiveness of AL 1064 mg every 2 months, initiated using the 1-day AL initiation regimen, without further oral supplementation beyond day 1, in patients hospitalized for acutely exacerbated schizophrenia with subsequent transition to outpatient care. In short-term and long-term studies, AL was generally well tolerated at initiation and during acute and maintenance treatment. Pharmacokinetic, efficacy, and safety characteristics support the use of AL across inpatient and outpatient treatment settings. Plain Language Summary: Treatment of schizophrenia with continuous antipsychotic medication has been shown to improve symptoms, daily functioning, and quality of life. One important option for antipsychotic treatment is a long-acting injectable medication. Antipsychotic injections can be administered weeks or months apart in place of daily oral medication. Aripiprazole lauroxil is a long-acting injectable antipsychotic for adults with schizophrenia that has several important features; it provides continuous, stable medication after monthly, every-6-week, or every-2-month injections, and multiple dose options are available (see video abstract). In addition, patients can start treatment with aripiprazole lauroxil using either a 1-day or 21-day initiation regimen with their first dose. The 1-day initiation regimen allows people with schizophrenia to start treatment during a doctor’s office visit or during a brief stay in the hospital. In short-term studies, aripiprazole lauroxil significantly reduced symptoms of acute schizophrenia. In longer-term studies, side effects were similar to those expected when using oral aripiprazole, and symptoms improved over extended durations of treatment lasting up to 3.5 years. Aripiprazole lauroxil’s safety and efficacy profile and multiple dosing and initiation options make it a treatment option for schizophrenia in inpatient and outpatient settings.


  • Open Access

    Long-Term Safety, Tolerability, and Durability of Treatment Effect of Olanzapine and Samidorphan

    by Jacob S. Ballon, René S. Kahn, Christina Arevalo, Martin Dunbar, David McDonnell, Christoph U. Correll

    During up to 4 years of treatment, the combination of olanzapine/samidorphan was safe and well-tolerated, and patients’ symptoms remained stable.


  • Open Access

    Using qualitative exit interviews to explore schizophrenia burden and treatment experience in clinical trial patients

    by Adam Simmons, Amy K. O’sUllivan, Julia Carpenter-Conlin, Michelle K. Carty, Cory Saucier, David McDonnell

    Introduction: Qualitative research methods can be used to obtain a deeper understanding of patient experience by collecting information in the patients’ own words about their encounters, perspectives, and feelings. In this study, patients with schizophrenia were interviewed to capture their voice and to complement the quantitative data typically obtained in clinical trials.Methods: Semi-structured exit interviews were conducted with 41 patients who completed or prematurely discontinued from a phase 3, open-label trial (NCT02873208). The interview guide included open-ended questions on current and prior disease burden, symptoms, quality of life, and treatment experiences. Steps taken to reduce interview stress and secure the validity of data included interviewer sensitivity training specific to mental health conditions and schizophrenia, use of in-person interviews whenever possible and use of videoconferencing for remote interviews to promote trust and comfort, and working closely with clinical site staff to identify patient eligibility and willingness to participate. Transcripts based on audio recordings were content coded and analyzed using thematic analysis; a post-hoc quantitative content analysis was conducted.Results: Patients reported that the symptoms of schizophrenia negatively impacted their work, relationships, self-esteem, emotional health, and daily activities. Most patients had positive experiences with medications that alleviated hallucinations, depression, and anxiety. However, side effects of medications were associated with negative impacts on physical, emotional, behavioral, and cognitive health. Lack of energy/drowsiness, weight gain, mood changes, and involuntary movements were the most common side effects reported with the use of antipsychotic medications. Patients reported unmet treatment needs related to better symptom control and to improved social and physical functioning.Conclusion: Collection of qualitative information within a schizophrenia clinical development process provides value and insights into patients’ views on burden of illness, experiences with previous medications, and experiences following participation in a clinical trial and can inform design for future studies.


  • Open Access

    Comment on “Opioid antagonists to prevent olanzapine-induced weight gain: A systematic review”

    by Mark S. Todtenkopf, Christoph U. Correll, Marni E. Harris-White, Michael J. Doane, David McDonnell

    Dear Editor:A recent systematic review by Laguado and Saklad highlighted the importance of addressing olanzapine-associated weight gain.1 While highly efficacious, olanzapine use has been limited by its propensity to cause significant weight gain. The authors considered the role of opioid antagonists in this setting by reviewing efficacy and safety data from the clinical development program of combination olanzapine and samidorphan (OLZ/SAM), concluding in part that samidorphan effectively mitigates olanzapine-associated weight gain. We provide comments on the authors' methodology, as their conclusions may underestimate weight gain mitigation with OLZ/SAM.We suggest that a more precise estimate of OLZ/SAM's weight mitigation benefit would be obtained by (1) analyzing separately the studies that were of sufficient duration to detect differences in weight gain from those that were not, and (2) weighting these study results before calculating the mitigating effect of OLZ/SAM on olanzapine-associated weight gain.Trials by Martin et al, Correll et al, and Kahn et al were of adequate duration (12, 24, and 12 weeks, respectively) to evaluate the targeted differences in treatment-associated weight gain between OLZ/SAM and olanzapine.2-4 In each of these studies, weight gain trajectories for OLZ/SAM and olanzapine were initially similar but then diverged between 4 and 6 weeks of treatment, after which weight gain plateaued in OLZ/SAM-treated patients but continued to increase over time in olanzapine-treated patients. Silverman et al and Potkin et al conducted 3-week and 4-week studies, respectively, that were not of suitable duration to use in calculations of the weight mitigation benefit of OLZ/SAM.5,6Additionally, to obtain a more precise estimate of OLZ/SAM's weight mitigation benefit, the results should be weighted by the sample size of each study. Aggregating outcomes of different studies without considering differences in sample sizes can lead to inaccurate estimates of an intervention's magnitude of effect7,8 that are avoided by using accepted weighting procedures.7Furthermore, in discerning the true weight mitigation benefit of OLZ/SAM, only studies combining 10 mg of samidorphan with olanzapine are of relevance, as 10 mg is the only dose approved by the United States Food and Drug Administration for use in OLZ/SAM. Last, the description of the number needed to harm (NNH) may be misinterpreted by readers as harm associated with the use of OLZ/SAM because the authors did not present NNH as a negative value. By convention, the use of either a negative NNH or the number needed to treat (NNT), rather than NNH, would communicate more clearly the treatment benefit (ie, the weight-mitigating effect of treatment with OLZ/SAM compared with olanzapine).Given these considerations and based on studies that were of sufficient duration and designed to evaluate weight gain in patients with serious mental illness, OLZ/SAM's weight mitigation benefit versus olanzapine ranged from −1.33 to −1.9 kg in trials lasting 12 to 24 weeks2-4; however, the benefit may be greater over longer treatment durations because weight gain plateaus with OLZ/SAM treatment but continues to increase with olanzapine treatment.In summary, the methodologies used by the authors may have underestimated the weight-mitigating effect of OLZ/SAM on olanzapine-associated weight gain.1 To assess the magnitude of this effect accurately, only studies of duration sufficient for assessing this outcome should be included, results of included studies should be weighted, and estimates of effect size should be calculated. Finally, while olanzapine-associated weight gain tends to continue over the long-term, results from open-label studies suggest that weight gain stabilizes during long-term OLZ/SAM treatment.9,10 Further characterizing the weight gain mitigation effect provided by OLZ/SAM versus olanzapine during treatment courses longer than 6 months' duration may be beneficial to clinicians and to patients, many of whom require long-term and continuous antipsychotic treatment.11

  • Open Access

    Olanzapine/Samidorphan in Young Adults With Schizophrenia, Schizophreniform Disorder, or Bipolar I Disorder Who Are Early in Their Illness

    by René S. Kahn, John M. Kane, Christoph U. Correll, Christina Arevalo, Adam Simmons, Christine Graham, Sergey Yagoda, Beibei Hu, David McDonnell

    In patients with early-phase schizophrenia or bipolar disorder, combination olanzapine and samidorphan resulted in less weight gain at week 12 than olanzapine alone. Antipsychotic efficacy was similar between the treatment groups.


  • Open Access

    Olanzapine/samidorphan combination consistently mitigates weight gain across various subgroups of patients

    by Jonathan M. Meyer, Adam Simmons, Ying Jiang, Christine Graham, Sergey Yagoda, David McDonnell

    Objective: A combination of olanzapine and the opioid receptor antagonist samidorphan (OLZ/SAM) has been approved in the United States for the treatment of adults with schizophrenia or adults with bipolar I disorder. In a phase 3 study in adults with schizophrenia (ENLIGHTEN-2), OLZ/SAM treatment was associated with significantly less weight gain compared with olanzapine. Prespecified subgroup analyses explored the consistency of the weight mitigation effect of OLZ/SAM vs olanzapine across demographic subgroups in ENLIGHTEN-2.Methods: The multicenter, randomized, double-blind ENLIGHTEN-2 study (NCT02694328) included outpatients aged 18–55 years with a diagnosis of schizophrenia based on DSM-5 criteria, a body mass index (BMI) of 18 to 30 kg/m2, and stable body weight (self-reported change ≤5% for ≥3 months before study entry). Patients were randomized 1:1 to receive OLZ/SAM or olanzapine for 24 weeks. Co-primary endpoints (previously reported) were percent change in body weight and proportion of patients with at least 10% weight gain from baseline at week 24. Prespecified exploratory subgroup analyses by sex, age, self-reported race, and baseline BMI were conducted.Results: At week 24, treatment with OLZ/SAM resulted in numerically less percent weight gain than with olanzapine across all subgroups evaluated. The proportion of patients with at least 10% weight gain was smaller in each subgroup treated with OLZ/SAM vs olanzapine.Conclusion: In these exploratory subgroup analyses from the ENLIGHTEN-2 study, weight-mitigating effects of OLZ/SAM vs olanzapine were observed consistently across patient subgroups and were in line with results from the overall study population.


  • Open Access

    Weight Gain and Comorbidities Associated with Oral Second-Generation Antipsychotics: Analysis of Patients with Bipolar I Disorder or Schizophrenia

    by Jonathan M. Meyer, Leona Bessonova, Haley S. Friedler, Kathleen M. Mortimer, Harry Cheng, Thomas Brecht, Amy K. O’sullivan, Hannah Cummings, David McDonnell, Michael J. Doane

    ObjectiveClinically significant weight gain (CSWG) is associated with increased morbidity and mortality. This study describes CSWG and comorbidities observed in patients with bipolar I disorder (BD-I) and schizophrenia (SZ) after initiating select second-generation antipsychotics (SGAs).MethodsPercent change in weight, CSWG (=7% weight increase), and incident comorbidities within 12 months of treatment were assessed among patients initiating oral SGAs of moderate-to-high weight gain risk using medical records/claims (OM1 Real-World Data Cloud; January 2013-February 2020). Oral SGAs included clozapine (SZ), iloperidone (SZ), paliperidone (SZ), olanzapine, olanzapine/fluoxetine (BD-I), quetiapine, and risperidone. Outcomes were stratified by baseline body mass index and reported descriptively.ResultsAmong patients with BD-I (N = 9142) and SZ (N = 8174), approximately three-quarters were overweight/obese at baseline. During treatment (mean duration = 30 weeks), average percent weight increase was 3.7% (BD-I) and 3.3% (SZ). Average percent weight increase was highest for underweight/normal weight patients (BD-I = 5.5%; SZ = 4.8%), followed by overweight (BD-I = 3.8%; SZ = 3.4%) and obese patients (BD-I = 2.7%; SZ = 2.3%). Within 3 months of treatment, 12% of all patients experienced CSWG. A total of 11.3% (BD-I) and 14.7% (SZ) of patients developed coronary artery disease, hypertension, dyslipidemia, or type 2 diabetes within 12 months of treatment; development of comorbidities was highest among overweight/obese patients and those with CSWG.ConclusionsPatients who were underweight/normal weight at baseline had the greatest percent change in weight during treatment. Increased comorbidities were observed within 12 months of treatment, specifically among overweight/obese patients and those with CSWG. The magnitude of weight gain and development of comorbidities were similar for patients with BD-I and SZ.FundingAlkermes, Inc.

  • Open Access

    An Evidence-Based Review of OLZ/SAM for Treatment of Adults with Schizophrenia or Bipolar I Disorder [Corrigendum]

    by Leslie Citrome, Christine Graham, Adam Simmons, Ying Jiang, Mark S Todtenkopf, Bernard Silverman, Lauren DiPetrillo, Hannah Cummings, Lei Sun, David McDonnell

    Corrigendum for the article An Evidence-Based Review of OLZ/SAM for Treatment of Adults with Schizophrenia or Bipolar I Disorder

  • Reduced Risk Across Multiple Cardiometabolic Risk Factors With OLZ/SAM Compared With Olanzapine: Results From a 24-Week Phase 3 Study

    by Christoph U. Correll, Evan Stein, Christine Graham, Lauren DiPetrillo, Sarah Akerman, Arielle D. Stanford, Ying Jiang, Sergey Yagoda, David McDonnell, Craig Hopkinson


  • Open Access

    Long-term safety and durability of effect with a combination of olanzapine and samidorphan in patients with schizophrenia: results from a 1-year open-label extension study

    by Sergey Yagoda, Christine Graham, Adam Simmons, Christina Arevalo, Ying Jiang, David McDonnell

    Background: Combination olanzapine and samidorphan (OLZ/SAM), in development for schizophrenia and bipolar I disorder, is intended to provide the efficacy of olanzapine while mitigating olanzapine-associated weight gain. OLZ/SAM safety, tolerability, and efficacy from a 52-week open-label extension study in patients with schizophrenia are reported.Methods: Patients previously completing the 4-week, double-blind ENLIGHTEN-1 study switched from OLZ/SAM, olanzapine, or placebo to OLZ/SAM. Assessments included adverse events (AEs), weight, vital signs, Positive and Negative Syndrome Scale (PANSS), and Clinical Global Impression-Severity (CGI-S) scores. Baseline was prior to first dose of OLZ/SAM in the extension study.Results: In total, 281 patients enrolled, 277 received ≥1 OLZ/SAM dose, and 183 (66.1%) completed 52 weeks. Reasons for discontinuation included patient withdrawal (15.5%), loss to follow-up (6.9%), AEs (5.8%), and lack of efficacy (1.8%). AEs were reported in 136 (49.1%) patients; increased weight (13%) and somnolence (8%) were most common. Ten serious AEs were reported in eight patients (2.9%); none were considered treatment related. There were no deaths. Mean (SD) baseline weight was 79.1 (17.8) kg. Mean weight change from baseline to week 52 was 1.86 kg (2.79% increase). PANSS total and CGI-S scores continued to decline over 52 weeks (mean [95% CI] changes from baseline to week 52: −16.2 [−18.5, −14.0] and −0.9 [−1.0, −0.8], respectively).Conclusion: OLZ/SAM was generally well tolerated in this extension study; most patients completed the 52-week treatment period with sustained improvement in schizophrenia symptoms. Mean increases in weight stabilized by week 6 with limited subsequent change through end of treatment.